You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201531 - 201540 of 207728 results
  1. Multiplexed Bead-based In Vitro Pediatric Allergy Test

    SBC: AMBERGEN, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): This proposal focuses on the development of a high-throughput, high sensitivity, low blood-volume, multiplex system for in vitro diagnosis of pediatri food allergies. Allergies comprise a group of immune disorders constituting the 6th leading cause of chronic disease in the US. In the case of pediatric allergies, over 50 million children ar affected, a number w ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Quantitation and Genotyping of HCV RNA by Time Resolved Lanthanide Luminescence

    SBC: WAVE 80 BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a single-stranded RNA virus of roughly 9.4 kb estimated to affect 200 million people worldwide. In the U.S., where it is estimated that 4.1 million are infected, HCV accounts for 60-70% of chronic hepatitis and 50% of cirrhosis, end-stage liver disease, and hepatocellular carcinoma, causing an estimated 12,000 deaths annually. From 19 ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Inexpensive multiplexed ligation probe assay to genotype drug resistant M.tubberc

    SBC: Investigen, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Diagnosis of tuberculosis (TB) is the weakest link in global TB control and drug resistance complicates the selection of an appropriate treatment course. The most widely used diagnostic test, sputum smear microscopy, iscumbersome, insensitive, involves multiple patient visits and cannot detect multi drug or extensively drug resistant tuberculosis (MDR/XDR-TB). ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development

    SBC: GENVEC, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The development of an effective malaria vaccine is a high global health priority. Malaria is the most burdensome parasitic disease of man, exacting an estimated toll of 863,000 deaths and 243 million clinical cases peryear. There is an urgent need for a safe and effective malaria vaccine. An abundance of data in rodents, non-human primates and humans indicate t ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid Detection of Periprosthetic Joint Infection

    SBC: ECI BIOTECH            Topic: NIAID

    DESCRIPTION (provided by applicant): The research proposed in this application aims to develop ECI Biotech's promising technology toward improved diagnosis of periprosthetic joint infection (PJI), and reduction in the unwarranted antimicrobial intervention. Criteria for PJI diagnosis have not been standardized in clinical practice, and symptoms of PJI are sometimes difficult to distinguish f ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Tetravalent Vaccines for Dengue Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmission in tropical and subtropical areas and vaccines are an urgent public health priority. Although dengue rarely occurs in the continental United States, it is endemic in Puerto Rico, and in many popular ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Vaccination with purified, cryopreserved, infectious Plasmodium vivax sporozoites

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Plasmodium vivax (Pv) is the 2nd most important human malaria parasite, causing gt 80 million cases annually. However, efforts to prevent and control Pv malaria face major challenges of drug resistance and repeated relapses from dormant forms. Moreover, Pv vaccine development has been impeded, because Pv parasites cannot be grown in continuous in vitro culture. ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Multi-stage multi-antigen Vaccine for interrupting Malaria Transmission

    SBC: PROTEIN POTENTIAL LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): We believe that eradication of malaria is achievable but not without a potent vaccine that interrupt malaria transmission (VIMT) transmission blocking vaccine. A logical and promising strategy is to combine target antigens from multiple stages to potently prevent transmission. To prevent transmission a vaccine should target the pre-erythrocytic (sporozoite and ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccine research. An increasing number of human monoclonal antibodies (mAbs) have been isolated in recent years from individuals who show remarkably broad and potent neutralizing responses. Coupled with pas ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Delivery of passive immunity against HIV using commensal vaginal Lactobacillus bi

    SBC: OSEL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Women bear the brunt of the global AIDS epidemic due in part to their inherent social and biological vulnerability. Biologically, the cervical and vaginal mucosae are vulnerable targets for HIV transmission. In healthywomen of childbearing age, mucosal antibodies and microflora, including Lactobacillus jensenii, help protect these surfaces and serve to block th ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government